Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma, Non-Hodgkin 56Lymphoma, Large B-Cell, Diffuse 55Lymphoma, Follicular 48Lymphoma 47Leukemia, Lymphocytic, Chronic, B-Cell 45Lymphoma, Mantle-Cell 41Lymphoma, B-Cell, Marginal Zone 24Lymphoma, B-Cell 22Waldenstrom Macroglobulinemia 17Hodgkin Disease 16Burkitt Lymphoma 16Leukemia 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Recurrence 10Lymphoma, Large-Cell, Immunoblastic 9Neoplasms 7Multiple Myeloma 6Myelodysplastic Syndromes 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, T-Cell, Cutaneous 4Lymphoma, Large-Cell, Anaplastic 4Lymphoma, Extranodal NK-T-Cell 4Leukemia, Hairy Cell 4Intraocular Lymphoma 4Hematologic Neoplasms 4Sezary Syndrome 3Mycosis Fungoides 3Lymphoma, T-Cell 3Lymphoma, Primary Effusion 3Immunoblastic Lymphadenopathy 3

Interventions

Rituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Ataxia × Rituximab × Clear all
NCT00244361 2011-05-10

Effectiveness of Rituximab in Pediatric OMS Patients.

National Pediatric Neuroinflammation Organization, Inc.

Phase 1/2 Completed
25 enrolled

Ataxia, Myoclonus, Ocular Motility Disorders, Opsoclonus-Myoclonus Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡